Clinical Trial Detail

NCT ID NCT03411031
Title Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

multiple myeloma

Therapies

Elotuzumab + Lenalidomide

Dexamethasone

Age Groups: adult senior

No variant requirements are available.